The TIGeR-PaC Study

A clinical research study in people with pancreatic cancer is now enrolling

Pancreatic cancer is on the rise. The number of cases of pancreatic cancer is also increasing globally. In 2018, approximately 460,000 new cases of pancreatic cancer were reported.
Although advances in cancer treatments continue to grow, there is still a great need for new therapies. Promising new treatment options and ways to deliver these treatments more effectively are now under development.

Do you have locally advanced pancreatic cancer that cannot be treated surgically and has not spread to other parts of your body?

  • We are currently looking for men and women who have been diagnosed with pancreatic cancer who may be interested in joining a clinical research study called the TIGeR-PaC Study.
  • The TIGeR-PaC Study is investigating a new way of administering chemotherapy in people with pancreatic cancer.
  • If you qualify for the study, study medicine and all study-related care will be provided at no additional cost by your insurance or Company conducting the TIGeR-PaC Study.
  • Participation in the TIGeR-PaC Study is voluntary, and you can leave the study at any time, for any reason.

Patient Stories

Watch news reports of real patients undergoing targeted diagnostic and therapeutic infusion using the RenovoCath, which is FDA cleared and now being investigated in an active clinical trial to prove extended median survival and improved quality of life.

RenovoRx on Twitter

Have Questions? We Have Answers.